High-Risk Thyroid Cancer: Neoadjuvant Pembrolizumab Study

We are studying the effects of pembrolizumab as a pre-surgery treatment for patients with high-risk thyroid cancers. The goal is to see if it improves outcomes and understand how the body responds to this therapy.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Keytruda
Keytruda is a cancer medicine that helps the immune system find and fight tumor cells.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Pembrolizumab
Pembrolizumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein called PD-1.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Endocrine and Metabolic Surgery
La Massimina-Casal Lumbroso, Italy
Fondazione IRCCS Istituto Nazionale Dei Tumori
Medical Oncology Unit 3
Milan, Italy
Fondazione IRCCS Policlinico San Matteo
otolaryngology surgery
Pavia, Italy

Sponsor: Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.